The present paper reports the results which were obtained in a clinical trial of cefadroxil (CDX), a new oral cephalosporin, in the pediatric field. (1) A total of 20 patients with infectious diseases including 9 urinary tract infection, 7 acute tonsillitis, 2 scarlet fever, 1 pyodermia and 1 recurrent bronchitis were treated with CDX. Of the 20 cases, the clinical response was excellent in 15 cases (75%), good in 4 cases (20%), and fair in 1 case (5%). (2) Efficacy classified by causative organisms was as follows; E. coli, 100%; S. pyogenes, 87.5%. (3) Neither adverse reactions nor abnormal laboratory results were observed.